# Distal gene regulation mediated by non-coding RNAs contributes to germline risk for

# breast and prostate cancer

Nolan Cole<sup>1</sup>, Paige Lee<sup>2</sup>, Tommer Schwarz<sup>3,4</sup>, Pan Zhang<sup>5</sup>, Matthew L. Freedman<sup>6,7</sup>, Alexander

Gusev<sup>6</sup>, Sara Lindström<sup>10,11</sup>, Michael J. Gandal<sup>5,12,13</sup>, Bogdan Pasaniuc<sup>4,12,13</sup>, Arjun

Bhattacharya<sup>4,14\*</sup>

- 1. Department of Statistics, Brigham Young University, Provo, UT, United States
- 2. Department of Statistics, University of California, Los Angeles, CA, United States
- 3. Bioinformatics Interdepartmental Program, University of California, Los Angeles, CA, United States
- 4. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, United States
- 5. Department of Psychiatry, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- 6. Department of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA, USA
- 7. The Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA, USA
- 8. Program in Neurobehavioral Genetics, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- 9. Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- 10. Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA
- 11. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- 12. Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- 13. Department of Computational Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- 14. Institute of Quantitative and Computational Biosciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

\*Corresponding author: Arjun Bhattacharya (abtbhatt@ucla.edu)

# 1 ABSTRACT

2 Genome-wide association studies (GWAS) have identified numerous genetic loci associated 3 with breast and prostate cancer risk, suggesting that germline genetic dysregulation influences 4 tumorigenesis. However, the biological function underlying many genetic associations is not 5 well-understood. Previous efforts to annotate loci focused on protein-coding genes (pcGenes) 6 largely ignore non-coding RNAs (ncRNAs) which account for most transcriptional output in human cells and can regulate transcription of both pcGenes and other ncRNAs. Though the 7 8 biological roles of most ncRNAs are not well-defined, many ncRNAs are involved in cancer 9 development. Here, we explore one regulatory hypothesis: ncRNAs as trans-acting mediators of 10 gene expression regulation in non-cancerous and tumor breast and prostate tissue. Using germline genetics as a causal anchor, we categorize distal (>1 Megabase) expression 11 quantitative trait loci (eQTLs) of pcGenes significantly mediated by local-eQTLs of ncRNAs 12 13 (within 1 Megabase). We find over 300 mediating ncRNAs and show the linked pcGenes are enriched for immunoregulatory and cellular organization pathways. By integrating eQTL and 14 cancer GWAS results through colocalization and genetically-regulated expression analyses, we 15 detect overlapping signals in nine known breast cancer loci and one known prostate cancer 16 17 locus, and multiple novel genetic associations. Our results suggest a strong transcriptional impact of ncRNAs in breast and prostate tissue with implications for cancer etiology. More 18 broadly, our framework can be systematically applied to functional genomic features to 19 20 characterize genetic variants distally regulating transcription through *trans*-mechanisms.

21

#### 22 SIGNIFICANCE

This study identifies non-coding RNAs that potentially regulate gene expression in *trans*pathways and overlap with genetic signals for breast and prostate cancer susceptibility, with implications for interpretation of cancer genome-wide association studies.

26

#### 27 INTRODUCTION

28 Genome-wide association studies (GWAS) of cancer risk have revealed risk-associated alleles at hundreds of genetic loci, with breast and prostate cancer GWAS yielding the largest number 29 of associations (1,2). Through integration with transcriptomic and functional genomics datasets, 30 31 the proposed target genes for many of these risk loci have been found in protein-coding regions 32 of the genome (1–4). However, many risk variants fall in non-coding regions of the genome and, for these variants, identifying the likely biological mechanism is challenging. One proposed 33 mechanism for GWAS-identified risk variants is *trans*-acting pathways: a GWAS variant affects 34 35 a regulatory feature, like a transcription factor, in proximity, which then affects genes located far away from the GWAS variant. Particularly, one study identified GWAS risk variants for breast 36 cancer that confer trans-effects through transcription factors, like ESR1, MYC, and KLF4 (5). 37 Another potential mechanism by which GWAS variants in non-coding regions affect risk is 38 39 mediation of *trans*-acting effects of genetic variants through non-coding RNAs (ncRNAs). 40

Although ncRNAs do not code for proteins, they account for nearly 60% of transcriptional output 41 in human cells and interact with a complex network of genes, transcripts, and proteins with 42 43 widespread effects on cell biology (6,7). Some ncRNAs, like microRNAs (miRNAs), target and degrade mRNA transcripts of specific genes and link to regulatory networks that include multiple 44 ncRNAs and protein-coding genes (pcGenes). These complex interactions between ncRNAs 45 46 and pcGenes support the hypothesis that ncRNAs have key roles in cellular pathways (6,8,9). 47 Specific ncRNAs have been shown to leave their transcription site and regulate gene expression at genomic regions far from their transcription start site (8,9). However, regulatory 48 impacts of ncRNAs on transcription of pcGenes are generally uncategorized, especially in a 49 systematic fashion (8). 50

51

ncRNAs have shown associations with the onset and progression of different cancers, are
enriched in multiple tumor types, and are even therapeutic targets, as they act as regulators of
genes in important tumorigenic or progressive networks (10). For example, the long ncRNA *XIST* exerts oncogenic and metastatic effects in multiple cancer types (11). Profiling and deep
sequencing of ncRNAs have shown that perturbing ncRNA biogenesis affects amplification,
deletion, and normal epigenetic and transcriptional regulation (10,12–14); accordingly, ncRNAs
can act as oncogenes or antagonize tumor suppressors.

59

60 However, as most ncRNA mechanisms in cancer tumorigenesis or progression have been 61 categorized on a case-by-case basis (13,14), mechanistic impacts of ncRNAs have not been 62 explored systematically. Bioinformatics analyses that leverage high-throughput genomics have investigated the role of ncRNAs through computational target prediction or differential 63 64 expression analyses. Although these computational methods have elucidated potential roles of 65 ncRNAs in cancer, they have limitations, including computational feasibility and functional translation of sequence similarity methods (15) and reverse causality for differential expression 66 analyses (i.e., differential expression more likely reflects consequences of disease) (16). 67

68

One systematic approach to identifying potential *trans*-mechanisms of regulation is to use 69 70 genetic variants as causal anchors. A prevailing thought is that distal expression quantitative 71 trait loci (eQTLs) of genes, where the genetic variant is far away from the gene (more than 1 72 Megabase, or Mb), are often themselves local-, or *cis*-acting, QTLs of a regulatory feature (17-73 22). We emphasize that the modifiers "local" and "distal" refer merely to distances in the 74 genome (i.e., within or outside 1 Mb, respectively), whereas *cis*- and *trans*-acting refer to the 75 biological mechanism (i.e., direct or indirect interaction, respectively). Molecular features, like 76 ncRNAs, that have potential trans-acting regulatory effects can be identified through mediation 77 analyses, either at variant- or gene-level (18,21,23,24). Not only can these analyses point to

78 distal relationships between ncRNAs and pcGenes, but they can point to genetic variants 79 associated with disease etiology with potential distal effects in the transcriptome. 80 Here, we systematically map distal-eQTLs of pcGenes that are potentially mediated by local-81 82 eQTLs of ncRNAs in non-cancerous and tumor prostate and breast tissue, using data from the Genotype Tissue-Expression (GTEx) Project (25) and The Cancer Genome Atlas (TCGA) (26). 83 We then employ colocalization (27) and genetically-regulated expression analysis (28) to 84 identify overlaps in eQTLs and GWAS signals for both overall and molecular subtype-specific 85 86 breast (2) and overall prostate (1) cancer risk. In total, our work shows the widespread 87 transcriptomic impact of genetically-mediated portion of ncRNAs and that this impact has key associations with cancer susceptibility. This approach provides a rigorous framework to not only 88 categorize functional hypotheses of distal regulatory effects of ncRNAs but also other regulatory 89 90 molecular features.

91

#### 92 MATERIALS AND METHODS

93 A graphical representation of our methods is provided in **Supplemental Figure S1**.

94

# 95 Data acquisition and processing

We used pre-processed genotype, transcriptomic, and covariate data for non-cancerous 96 97 mammary and prostate tissue from the Genotype-Tissue Expression Project (GTEx) v8 (25) and 98 breast and prostate tumor tissue from The Cancer Genome Atlas (TCGA) (26). We included only individuals of European ancestry due to the small sample sizes available for other 99 100 demographics (N = 337 for GTEx breast, N = 186 for GTEx prostate, N = 437 for TCGA 101 breast, N = 349 for TCGA prostate). For both GTEx and TCGA, we only consider SNPs and genes on autosomes, restricted to SNPs with minor allele frequency greater than or equal to 102 1%, and excluded SNPs that deviated from Hardy-Weinberg equilibrium at  $P < 10^{-6}$ . 103

104

105	We used the BioConductor package <i>biomaRt</i> for ENSEMBL gene biotype annotations (29).
106	Using these annotations, we defined pcGenes as those labeled "protein-coding" and non-coding
107	RNAs (ncRNAs) as those labeled otherwise; we exclude transcripts labelled as "pseudogenes".
108	These annotations included 16,582 pcGenes and 5,650 ncRNAs in GTEx breast, 16,827
109	pcGenes and 5,862 ncRNAs in GTEx prostate, 21,648 pcGenes and 1,261 ncRNAs in TCGA
110	breast, and 15,773 pcGenes and 548 ncRNAs in TCGA prostate. We considered all provided
111	GTEx covariates: 5 genotype-based principal components (PCs), up to 60 probabilistically-
112	estimated expression residuals (PEER) factors, age, sex, and sequencing platform and protocol
113	(25). For TCGA, we calculated genotype PCs using PLINK v1.93 (30), calculated up to 50
114	hidden components of expression (HCP) using Rhcpp (31,32), and included the following
115	covariates: age, estrogen receptor subtype, menopausal status, and disease pathological stage.
116	For prostate tumors, we include the following covariates: age, sequencing platform, and
117	protocol.
118	
119	We integrated eQTL results with GWAS summary statistics for overall and subtype-specific
120	breast and overall prostate cancer risk. We obtained European-ancestry specific overall and
121	subtype-specific GWAS summary statistics for breast cancer risk from the BCAC Consortium
122	(2). We studied 5 intrinsic breast cancer molecular subtypes, defined by combinations of
123	estrogen (ER)-, progesterone (PR)-, and human epidermal growth factor receptor (HER2) and
124	tumor grade (2): Luminal A-like (ER + and/or PR + , HER2-, grade 1 or 2); (2) luminal B-

like/HER2-negative (ER + and/or PR + , HER2-, grade 3); (3) luminal B-like/HER2-positive

126 (ER + and/or PR + , HER2 +); (4) HER2-positive/non-luminal (ER- and PR-, HER2+), and (5)

127 TNBC (ER-, PR-, HER2-). We obtained European-ancestry specific GWAS summary statistics

128 for prostate cancer risk from the PRACTICAL Consortium (1).

129

### 130 eQTL mapping

We used a multiple linear regression model in *MatrixEQTL* to detect local- and distal-eQTLs (33). Here, we define a local-eQTL as a variant within 1 Mb of the gene body and a distal-eQTL as a variant outside the 1 Mb window. eQTLs outside this 1 Mb window are unlikely to have direct effects on the promoters or enhancers of the gene and are more likely to have *trans*acting mechanisms (17,18).

136

To determine a set of covariates that maximizes the number of detected distal-eQTLs for 137 138 pcGenes, we iterated on eQTL mapping using SNPs on Chromosome 22. For breast tumor tissue, we found that the optimized covariate set for local-eQTL mapping included all of the 139 140 clinical covariates (age, estrogen receptor subtype, menopause status, and disease pathological stage), the first 3 PCs, and the first 8 HCPs. For prostate tumor tissue, we included 141 142 age, sequencing platform, protocol as covariates and used 5 genotype PCs and 10 HCPs as the optimized set of covariates (31). For data from GTEx, we used the full set of provided covariates 143 for non-cancerous breast and prostate tissue local- and distal-eQTL mapping. We then run 144 genome-wide eQTL mapping with these optimized sets of covariates. 145

146

147 *Mediation analysis for distal-eQTL mapping* 

We first identify a testing triplet, consisting of (1) a SNP *s*, (2) a distal pcGene *G* associated with SNP *s* with nominal  $P < 10^{-6}$ , and (3) a set of local ncRNAs  $m_1, ..., m_M$ , all associated with SNP *s* with nominal  $P < 10^{-6}$ . As in previous distal-eQTL studies, we use a liberal P-value threshold to increase the number of testing triplets subjected to rigorous permutation-based mediation analysis (18,21,23). Next, we fit the following two sets of linear regressions for mediation analysis (21,23):

154 
$$Y_G = X_S \beta_S + M \beta_M + X_C \beta_C + \epsilon_G, \qquad \epsilon_G \sim N(0, \sigma^2 I_n)$$

where  $Y_G$  is a vector of expression for gene G,  $X_s$  is a vector of dosages for SNP s,  $\beta_s$  is the effect size of SNP s on gene G, M is the expression matrix of m ncRNAs,  $\beta_M$  is the effects of the M ncRNAs on  $Y_G$ ,  $X_C$  is a matrix of covariates, and  $\epsilon_G$  is a random error term. The *j*th ncRNA is modeled as

$$M_j = X_s \alpha_{M_j} + X_C \alpha_{C,j} + \epsilon_{M_j}, 1 \le j \le m, \qquad \epsilon_{M_j} \sim N(0, \sigma_{M_j}^2 I_n)$$

where  $M_j$  is the vector of expression for the *j*th ncRNA,  $\alpha_{M_j}$  is a vector of effects of SNP *s* on mediator  $M_j$ ,  $X_c$  is a matrix of covariates,  $\alpha_{c,j}$  is a vector of covariate effects on the mediator, and  $\epsilon_{M_j}$  represents a random error term.

163

We define the total mediation effect (TME) as  $TME = \alpha_M \cdot \beta_M$  and the mediation proportion (MP) as  $MP = \min(1, \frac{\alpha_M \cdot \beta_M}{\beta_s + \alpha_M \cdot \beta_M})$ . We test  $H_0: TME = 0$  vs.  $H_1: TME \neq 0$  via permutation testing with 166 10,000 draws.

167

# 168 Gene-based association testing (GBAT)

We applied GBAT (24) with modifications to identfy ncRNAs with genetically-regulated 169 expression (GReX) associated with distal pcGenes. First, we removed multi-mapped reads 170 171 using previously provided annotations (34). Then, we estimated the heritability of ncRNA expression using GCTA v1.93 (35), excluding genes with limited evidence of heritability (P > 172 0.05). Next, using leave-one-out cross-validation, we constructed the ncRNA GReX using SNPs 173 174 within 1 Mb using elastic net, LASSO (36) and SuSiE (37), excluding ncRNAs with crossvalidation  $R^2 < 0.01$ . We then employed MatrixEQTL to estimate the association between the 175 ncRNA GReX and distal pcGene expression, adjusting for the optimized set of covariates from 176 eQTL mapping (33). Lastly, to identify a set of SNPs that best explains distal ncRNA-pcGene 177 association, we used SuSiE fine-mapping with default parameters to define a 90% credible set 178 179 (37).

#### 180

# 181 Colocalization with cancer risk

To identify any potentially overlapping signals between local-eQTLs of ncRNAs, ncRNAmediated distal-eQTLs of pcGenes, and cancer risk, we employed the Bayesian colocalization method, *coloc* (27). *coloc* estimates the posterior probability that the same SNP explains both the eQTL and the GWAS signal at a given locus. We used standard parameters with default priors ( $p_1 = 10^{-4}$ ,  $p_2 = 10^{-4}$ , and  $p_{12} = 10^{-6}$ ) to estimate the colocalization posterior probability. We considered an eQTL signal to colocalize with a GWAS signal if the posterior probability of colocalization through one SNP (PP.H4 in Giambartolomei et al) was greater than 0.75 (27).

189

# 190 Genetically-regulated expression analysis of ncRNAs

191 We identified any cancer associations for the genetically-regulated expression (GReX) of any 192 ncRNAs that showed significant mediation of multiple distal-eQTLs of distant pcGenes. First, using elastic net regression, linear mixed modeling, and SuSiE, we built predictive models of 193 ncRNAs in both GTEx and TCGA data across breast and prostate tissue and select only models 194 with 5-fold cross-validation McNemar's adjusted  $R^2 > 0.01$  (28,36–38). We then employed the 195 196 weighted burden test and permutation test from the FUSION TWAS framework to detect a trait association with the GReX of an ncRNA (28). We define transcriptome-wide significance as P < P197 2.5 x  $10^{-6}$  and permutation test P < 0.05. 198

199

# 200 Data Availability

- 201 GTEx v8 data were obtained through dbGAP Study Accession phs000424.v8.p2. TCGA
- 202 genotype were obtained through dbGAP Study Accession phs000178.v11.p8 and expression
- and covariate data was obtained from the Broad GDAC Firehose repository
- 204 (<u>https://gdac.broadinstitute.org</u>). Prostate cancer GWAS summary statistics were obtained from
- 205 the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the

- 206 Genome (PRACTICAL) Consortium: <u>http://practical.icr.ac.uk/blog/wp-</u>
- 207 <u>content/uploads/uploadedfiles/oncoarray/MetaSummaryData/meta\_v3\_onco\_euro\_overall\_Chr</u>
- 208 <u>All\_1\_release.zip</u>. Breast cancer GWAS summary statistics were obtained from the Breast
- 209 Cancer Association Consortium (BCAC):
- 210 https://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/oncoarray-and-combined-summary-
- 211 <u>result/gwas-summary-associations-breast-cancer-risk-2020/</u>. Sample code for this analysis is
- 212 available at <a href="https://github.com/ColetheStatistician/ncRNAInBreastCancer/">https://github.com/ColetheStatistician/ncRNAInBreastCancer/</a>.
- 213

# 214 **RESULTS**

- In this work, we uncover hidden mechanisms contributing to genetic risk for breast and prostate
- 216 cancer mediated by ncRNAs, systematically exploring one regulatory hypothesis: distal
- 217 mediation of pcGene expression regulation in non-cancerous and tumor breast and prostate
- tissue (Figure 1). Specifically, we identify distal-eQTLs of protein-coding genes (pcGenes) that
- are significantly mediated by ncRNAs local to these distal-eQTLs and assess if they overlap
- 220 with genetic signal for cancer risk.
- 221

#### 222 Multiple ncRNAs mediate distal-eQTLs in breast and prostate tissue

- 223 Distal-eQTL mapping through mediation analysis
- We conducted distal-eQTL mapping through ncRNA mediation in GTEx (25) and TCGA (26).
- 225 The number of distal-eQTLs of pcGenes that are significantly mediated by ncRNAs are reported
- in **Table 1** and **Supplemental Table S1-2**. Distributions of TME and MP in tumor tissue showed
- a larger range than in non-cancerous tissue for both breast and prostate, and median TME and
- 228 MP were higher in tumor tissue (**Supplemental Figure S2**).
- 229
- 230 In non-cancerous breast tissue, pcGenes with cross-chromosomal distal-eQTLs with large
- ncRNA-mediated effects included *PUM1* and *PCBP1* (Figure 2A), both of which influence

232	tumorigenesis (39–41). In breast tumors, we found MT4 and GPRC6A have large mediated
233	distal effects. MT4 belongs to the metallothionein family involved in breast cancer
234	carcinogenesis (42,43), and GPRC6A is a part of the androgen receptor signaling pathway
235	(44,45). In non-cancerous prostate tissue, we detected large distal mediation effects for genes
236	such as RAF1, a proto-oncogene (46) and LGR5, a gene associated with prostatic regeneration
237	and overexpressed in prostate tumors (47). We also detected a number of olfactory receptors
238	(OR2T1, OR10G8, OR10S1) with large mediated effects in prostate tumor. Olfactory receptors
239	are associated with prostate cancer progression but generally have low expression in prostate
240	tumors (48,49).

241

Owing mainly to a larger set of nominally-significant distal-eQTLs in tumor tissues and larger 242 243 sample sizes in TCGA than GTEx, we found nearly four times as many significantly mediated 244 distal-eQTLs in tumor tissue compared to non-cancerous tissue. Among distal-eQTLs detected in tumor samples, we observed that multiple ncRNAs mediated distal-eQTLs with many different 245 pcGenes (vertical bands in **Figure 2A**). One such ncRNA in breast tumors is *LINC00301*, 246 showing significant mediation of 1,103 distal-eQTLs across 53 unique SNPs and 53 unique 247 248 pcGenes. Many of these pcGenes belong to the GAGE protein family, which promotes breast 249 cancer cell invasion and has shown evidence of distal genetic regulation (50,51). LINC00301 itself has been implicated in facilitating tumor progression and immune suppression, albeit in 250 251 lung cancer (52). Another example of such an ncRNA in breast tumors is miR-548f-4, a 252 commonly mutated microRNA in multiple cancers (53), mediating more than 300 distal-eQTLs 253 for 16 unique pcGenes, including GUCA2B, upregulated in breast cancer metastases (54), and 254 CYP2C9, a target of tamoxifen (55). In contrast, only two ncRNAs in non-cancerous breast 255 tissue showed significant mediation of more than 50 distal pcGenes. One of these genes, 256 FAM106A, mediated distal-eQTLs of 13 pcGenes, including BTN3A2, a prognostic marker for 257 breast cancer (56). In both non-cancerous and tumor breast tissue, three pcGenes (PRCC1,

258 *CYP2C9*, and *ATG14*) showed significant mediation through ncRNAs, though the sets of 259 pcGene targets across non-cancerous and tumor tissue are distinct.

260

In prostate tumors, LINC02903 showed significant mediation with the most distal-eQTLs (177 261 262 eQTLs across 8 pcGenes). These pcGenes include FABP9, an upregulated gene in prostate carcinomas with prognostic value (57), and MTNR1B, a gene harboring nominal risk variants for 263 prostate cancer (58). Another ncRNA with significant TME for nearly 100 distal-eQTLs across 264 20 pcGenes was SDHAP2. Many of these pcGenes have been implicated in prostate cancer 265 266 and metastasis pathways, including TMEM207, FADS6, MTNR1B, SLC26A8, and FGF23 (59-61). Similar to breast tissue, only two ncRNAs showed significant mediation of more than 20 267 distal eQTLs in prostate tissue: FBXO30-DT and SNHG2, which has been implicated in 268 tumorigenesis and proliferation in multiple cancers (62-64). A majority (22/26) of distal-eQTLs 269 270 mediated by FBX030-DT are for OVCH2, which has been implicated in prostate risk through GWAS (65,66). The majority of distal-eQTLs mediated by SNHG2 are for RAF1, a therapeutic 271 target for multiple cancers (46). We did not detect any shared ncRNAs or pcGenes across non-272 273 cancerous and tumor prostate tissue.

274

275 Gene-based distal-eQTL mapping

Next, we conducted gene-level distal eQTL mapping using GBAT (24) to identify ncRNAs that 276 277 are regulated by multiple weak local genetic effects and may have distal effects on pcGenes; 278 these ncRNAs are likely to be missed by the mediation framework. Comparing to mediated 279 pcGenes from mediation analysis (Table 1), we found a similar order of magnitude of pcGenes 280 with distal associations with ncRNAs using GBAT (Table 2). We again detected far more distal 281 ncRNA-pcGene directional associations in tumor compared to non-cancerous tissue (Table 2, 282 **Supplemental Table S1-2**). In addition, the distribution of ncRNA-pcGene effect sizes is shifted downwards in tumor tissue, compared to non-cancerous tissue, though the number of effect 283

sizes in these distributions are far less for non-cancerous tissue distal associations
(Supplemental Figure S2). In breast tumors, we found large distal genetic associations with
pcGenes like *OXNAD1*, an RNA-binding protein that is associated with pan-cancer survival
rates and involved with tumor invasion and metastasis (66,67), and *LCN9*, part of the lipocalin
family that promotes breast cancer metastasis (68). In prostate tumors, we detected multiple
large distal genetic associations with genes in the pro-proliferative keratin-associated protein
family (*KRTAP13-3*, *KRTAP13-4*, *KRTAP10-8*) (69) (Figure 2).

291

Though distal genetic effects of ncRNAs in non-cancerous breast or prostate tissue were sparse, we found three ncRNAs with genetic associations with pcGenes across both breast and prostate tissue: *LINC01678*, *FAM106A*, and *AP001056.1*. These ncRNAs also target the same pcGenes (*LOC102724159*, *CCDC144A*, *GATD3B*, and a paralog to *TRAPPC10*), all with no catalogued functions in cancer.

297

Again, in tumor-specific gene-gene associations, many ncRNAs had associations with multiple 298 pcGenes, leading to vertical bands in the location plots in Figure 2B. For example, in breast 299 300 tumors, LINC000906, a predicted miRNA sponge in breast tumors (70), was associated with 301 115 pcGenes. The largest association was with MS4A5, whose hypomethylation is shown to be prognostic for multiple cancer types (71,72). Another ncRNA associated with multiple different 302 303 pcGenes is LINC00115, a known promoter of breast cancer metastasis and progression (73-304 75). Many of these targets are related to interferons (IFNA17 and IFNW1), immune system 305 cytotoxicity (RAC2 and DDB2), or secretory proteins (PRH1 and PRH2).

306

In prostate tumors, *FAM138F* showed distal genetic associations with 57 distinct pcGenes,

308 many of which are involved in amino acid activation in prostate cancer (HDAC2, NT5DC1,

309 NUS1, and PREP) and protein stability (PDCD2, TCP1). Additionally TDRG1, shown to be

associated with progression and metastases in multiple cancers (76,77), showed multiple distal
genetic associations with pcGenes, including the cancer-initiating pluripotency factor *PRDM14*(78) and multiple genes related to olfactory stimulus (*OR10H3*, *OR2T1*, *OR51V1*, and *UGT2A1*)
(49). Taken together, these distal eQTL mappings suggest the ncRNAs have strong influences
on gene expression of multiple pcGenes in both non-cancerous and tumor tissue.

316 Overlap of miRNA-pcGene pairs with target prediction databases

317 For in-silico validation, we queried TargetScan (79,80), a database that curates computationally 318 predicted RNA targets of miRNAs, for any miRNAs that our analysis detected to mediate distaleQTLs of pcGenes. Out of 522 pairs of miRNAs and pcGenes across 72 unique miRNAs 319 identified through our analysis, we found that 184 pairs were included in the TargetScan 320 321 database (Supplemental Table S3). miRNA-pcGene pairs identified in our eQTL analysis are 322 found in TargetScan at an enrichment ratio of 8.2 (95% CI: [6.68, 10.09]), compared to the universe of all miRNA-target pairs in TargetScan (approximately 3.56 million) and roughly 323 159,000 miRNA-target pairs in TargetScan for the 72 miRNA families identified. A majority of 324 these miRNAs (82% of miRNAs detected in eQTLs) are conserved only across humans and 325 326 mice but well-annotated. Though this intersection with TargetScan does not implicate the 327 miRNA in distal regulation of the proposed pcGene, it provides some computational validation of this relationship using different methodology (sequence similarity vs. eQTL mapping). 328

329

330 Distal-eGenes are enriched for tumorigenesis and cancer progression gene pathways

To assess enriched biological processes or pathways by sets of prioritized pcGenes (called distal-eGenes), we conducted gene ontology enrichments (81). Overall, compared to all expressed pcGenes in the transcriptome, distal-eGenes in non-cancerous tissue (combining breast and prostate) were significantly enriched (FDR-adjusted P < 0.05) for many relevant ontologies: immune processes, genes targeted by epigenetic regulation, microRNA targets in

336 cancer, and oxidoreductase activity. In comparison, distal-eGenes detected in tumor tissue 337 showed enrichments mainly for chemical and sensory receptors and intermediate filament cytoskeleton (Supplemental Figure S3-4). Comparing tissue-prioritized distal-eGenes (breast-338 specific or prostate-specific pcGenes to the protein-coding transcriptome), we found distal-339 340 eGenes enrichments detected in prostate tissue for immune pathway ontologies, including the multiple activations of immune cells, and known tumorigenic pathways, like the JAK-STAT 341 cascade and PI3K-Akt signaling (82,83). We did not detect any significant enrichments for the 342 breast-specific distal-eGenes (Supplemental Figure S5). 343

344

345 We also conducted comparisons of distal-eGenes between non-cancerous and tumor state in both breast and prostate tissue (Figure 3). We find that, compared to distal-eGenes prioritized 346 in breast tumors, non-cancerous breast distal-eGenes were enriched for cytokine and leukocyte 347 production, response, and function, as well as membrane transport and binding. We observed 348 349 similar enrichments when we compared non-cancerous prostate distal-eGenes to those from prostate tumors, with additional cell death and morphogenesis ontologies enrichments. In 350 contrast, across both breast and prostate tissue, tumor-specific distal-eGenes, compared to 351 352 non-cancerous distal-eGenes, mainly showed enrichments for olfactory and chemical stimulus response, intermediate filament cytoskeleton localization, and epidermis development. These 353 ontologies are consistent with cancer progression, as olfactory receptors have been validated 354 355 as prognostic biomarkers in prostate cancers and are overexpressed in more aggressive breast 356 tumors (48,49,84,85), more aggressive breast cancers are enriched for genes that influence 357 epidermal growth (86) and cytoskeletal dysregulation is key to cancer cell invasion, progression, and metastasis (87-89). 358

359

360 Distal-eQTLs overlap with genetic signal for breast and prostate cancer risk

361 Lastly, we integrated these eQTL results with GWAS summary statistics for overall prostate and 362 overall and molecular subtype-specific breast cancer risk (1,2). A total of 84 detected ncRNAs are within 0.5 Mb of a GWAS SNP at P < 5 x  $10^{-8}$ , the majority for overall prostate and breast 363 cancer risk, which have the largest GWAS sample sizes (Figure 4A, Supplemental Table S1-364 365 2). Among pairs of ncRNAs and pcGenes where the ncRNA is 0.5 Mb from a GWAS SNP for either breast or prostate cancer risk, we identified 30 pairs (15 for overall breast cancer and 10 366 for LumA breast cancer, five for prostate cancer) where at least one of the ncRNA local-eQTL or 367 pcGene distal-eQTL colocalized with the GWAS signal at the locus with PP.H4  $\ge$  0.75 368 369 (Supplemental Figure S6, Supplemental Table S4). In total, we detected 10 independent overall or LumA-specific breast cancer risk GWAS signals and one independent prostate cancer 370 risk GWAS signal may be, in part, explained by distal genetics effects on pcGenes mediated by 371 local-ncRNAs. 372

373

We found that distal-eQTLs of CSH1 mediated by RFPL1S strongly colocalize with GWAS 374 signal for prostate cancer risk. (PP.H4 = 0.913) (Figure 4B). CSH1 codes for a somatotropin 375 hormone with paracrine signaling functions promoting cell division and growth in glands (90). 376 377 Using non-cancerous breast tissue eQTLs, we found strong colocalization with overall breast 378 cancer risk with local-eQTLs of RUSC1-AS1 and distal-eQTLs of SH2B1 (Figure 4C). Two different SNPs carried the largest posterior probability of colocalization for the local-379 380 (rs2297480) and distal-eQTLs (rs2075571), which are in moderate, yet statistically significant, linkage disequilibrium (D' = 0.51,  $R^2$  = 0.131, P < 0.001). RUSC1-AS1 has shown evidenced 381 382 silencing of genes through epigenetic signaling and is correlated with breast cancer progression (91,92). Additionally, SH2B1 is involved with cytokine signaling in cell proliferation and migration 383 384 (93). We also found strong colocalization with LumA-specific breast cancer risk with local-385 eQTLs of THBS3-AS1 and distal-eQTLs of SLC39A13 in non-cancerous breast tissue. The same SNP showed the maximum posterior probability for colocalization with both the local- and 386

distal-eQTL signal. Though the ncRNA has not been implicated in cancer risk or progression,
 *SLC39A13* facilitates metastasis in ovarian cancer by activating the Src/FAK signaling pathway
 (94).

390

391 For overall breast cancer risk, we also detect strong colocalization between eQTLs and GWAS 392 signals at the 17g21.31 locus. This locus houses a large, common inversion polymorphism associated with breast and ovarian cancer prognosis (95-97), as well as widespread 393 associations with multiple phenotypes (98–101). In particular, we found that the ncRNA 394 395 KANSL1-AS1 potentially mediates distal-eQTLs of multiple pcGenes. All but one of these pcGenes are on Chromosome 17, near the end of the 17q21.31 region; the last pcGene we 396 detected is TXNRD3 at 3q21.3. We were interested in disentangling effects of the H2 inversion 397 on gene expression and breast cancer risk, with the proposed causal diagram presented in 398 399 Figure 5A. First, we estimated haplotypes of the H2 inversion in GTEx (102). We found that KANSL1-AS1 and the associated pcGenes near 17q21.31 all have significant associations with 400 401 the H2 inversion (Figure 5B). Next, we reran mediation analysis for SNPs local to KANSL-AS1 and these detected pcGenes. After accounting for H2, the distal mediation signal of KANSL-AS1 402 403 is attenuated for all pcGenes except TXNRD3, suggesting that the inversion may be driving a significant portion of this signal. These analyses support our proposed causal model, that the 404 genetics of the H2 inversion affect expression of the local ncRNA KANSL-AS1 and the distal 405 406 pcGenes at the end of the inversion, which induces the eQTL associations (Figure 5A).

407

H2 inversion-adjusted colocalization analyses also support this model. A salient example is
shown in Figure 5D, with Manhattan plots from colocalization analysis of overall breast cancer
risk, local-eQTLs of *KANSL-AS1*, and distal-eQTLs of *CRHR1*. Colocalization analysis
unadjusted for H2, showed nearly-perfect colocalization for both eQTL signals with GWAS
(PP.H4 > 0.98 for both eQTLs), but after adjustments, the eQTL signals are completely

413 removed. In fact, the standardized effect sizes for local-eQTLs of KANSL1-AS1 showed strong 414 correlation with the standardized effect sizes for local-QTLs of the H2 inversion (Figure 5E), and the local-QTL signal for the H2 inversion strongly colocalized (PP.H4 = 0.99) with the 415 GWAS signal in the locus (Figure 5F). These results illustrate that the structural inversion in the 416 locus likely accounts for both cis-genetic control of KANSL1-AS1 and the associated pcGenes 417 further downstream on Chromosome 17. Furthermore, we emphasize further examination of the 418 H2 inversion and other structural variants in the locus for its impact on local and distal gene 419 expression, as well as cancer susceptibility, especially to elucidate if SNPs with widespread 420 421 local or distal associations with gene expression are affected by confounding due to structural 422 variants or other aberrations.

423

We also studied the cancer risk associations of ncRNAs with predicted large transcriptomic 424 effects using a genetically-regulated expression (GReX) approach (Methods). At P <  $2.5 \times 10^{-6}$ 425 and permutation P < 0.05, we identify 33 ncRNA-level associations (Figure 6, Supplemental 426 **Table S5**), predominantly for overall and subtype-specific breast cancer risk. Only one ncRNA, 427 SDHAP2, showed an association with overall prostate cancer risk (Figure 6); as we restrict to 428 429 ncRNAs mediating distal-eQTLs and not necessarily in known prostate cancer GWAS loci, we do not recover any ncRNAs detected by Guo et al's analysis of long-ncRNAs in prostate cancer 430 (103). A couple ncRNAs prioritized in associations of breast cancer risk using ncRNA GReX in 431 432 non-cancerous breast tissues have been previously noted. Common non-synonymous SNPs in 433 HCG9 have previously been implicated in breast cancer GWAS (104). In addition, CEROX1, a 434 cataloged post-transcriptional regulator of mitochondrial catalytic activity, has been implicated in distal alterations of metabolic pathways in breast cancers (14,105). ncRNAs prioritized in breast 435 tumor GReX-associations with breast cancer risk mainly included micro- and snoRNAs. Of 436 437 these, *miR-519d* has been shown to suppress breast cancer cell growth by targeting distal

438 molecular features(106,107). GReX associations prioritize these ncRNAs for further
439 investigation of their functional effects in breast and prostate tissue.

440

# 441 **DISCUSSION**

442 In this work, we systematically identify distal-eQTLs of pcGenes that are mediated by ncRNAs in non-cancerous and tumor breast and prostate tissue. We then show that many of these 443 ncRNA-mediated distal-eQTLs of pcGenes overlap with GWAS signals for breast and prostate 444 cancer, both with known GWAS loci and novel genetic loci undetected by GWAS. Taken 445 446 together, our results suggest that distal genetic effects on pcGenes mediated by ncRNAs may be a common mechanism underlying genetic signals and ncRNAs have a widespread role as 447 distal transcriptional regulators in prostate and breast tissue. We observed more distal ncRNA-448 pcGene directional associations in tumor than non-cancerous tissue, suggesting that tumor 449 450 tissues have multiple activated gene regulatory networks with potential effects on disease pathogenesis or progression. Our results implicating distal interactions between ncRNAs and 451 pcGenes are attractive for further in silico and experimental study. 452

453

454 We find many colocalized eQTL signals for ncRNAs and pcGenes in the 17q21.31 region, many of which have been prioritized by previous genetic association studies. For example, a 455 transcriptome-wide association study (TWAS) of estrogen receptor subtype-specific breast 456 457 cancer, identified ncRNA KANSL-AS1 (108), which has also been associated with ovarian 458 cancer (109). In our analysis, KANSL-AS1 mediated multiple breast cancer-associated pcGenes 459 further downstream on Chromosome 17 and colocalized almost perfectly with the GWAS association, suggesting widespread distal effects of KANSL-AS1 (108,110–114). However, after 460 461 accounting for the large and common H2 inversion in the 17q21.31 locus, the distal effects of 462 KANSL1-AS1 were largely attenuated, pointing to correlated effects of large structural aberrations on gene expression and disease etiology in this region (115–118). These results 463

also suggest that structural aberrations, like the 17q21.31 H2 inversion, have large effects on
gene expression, not only locally, but also distally. Our results also serve as a cautionary tale:
future gene expression analyses must delineate the eQTL signal in a locus from chromosomal
aberrations, especially when integrating with GWAS signals. Comprehensive analyses of the
transcriptomic effects of genomic aberrations in tumor tissue are needed.

469

We conclude with limitations of our study. First, we rely on Ensembl annotations of gene 470 biotypes to define our sets of ncRNAs and pcGenes. These annotations may be incomplete, 471 472 and accordingly, we may have ignored multiple non-coding transcripts (119). Next, as our localand distal-eQTL signals are the same cohor, we were unable to use multi-trait colocalization 473 methods, like moloc or Primo (120,121). A more flexible framework that allows for shared 474 molecular QTL signal could be developed to fully interrogate the mediated-distal QTL signal, in 475 476 the context of complex trait etiology. Next, we do not account for copy number variation or structural variation to disentangle these potentially disparate signals. Future studies should 477 consider corrections for inversions, translocations, or genomic imbalances. Lastly, due to limited 478 sample sizes in TCGA, we could not assess the effects of molecular subtype heterogeneity on 479 480 eQTL mapping in tumor tissue. Previously, subtype-specific genetic architecture of gene expression regulation has been suggested by previous studies (5,122,123), with some distal 481 genetic associations detected for genes that are highly predictive of molecular subtypes (124). 482 483 Robust subtype-specific analyses in breast cancer can be informative for both subtype-specific 484 risk and outcomes.

485

486 Our study provides evidence supporting *trans*-acting regulation by ncRNAs as a potential
487 biological mechanism relevant to breast and prostate cancer etiology. Particularly, our results
488 emphasize that larger samples of tissue- and tumor-specific transcriptomics datasets need to be

collected to study often ignored transcripts and explore more complex regulatory hypotheses tointerpret GWAS risk loci for cancer.

491

### 492 **REFERENCES**

- 493 1. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al.
- 494 Association analyses of more than 140,000 men identify 63 new prostate cancer
- 495 susceptibility loci. Nature Genetics. Nature Publishing Group; 2018;50:928–36.
- 496 2. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, et al. Genome-wide
- 497 association study identifies 32 novel breast cancer susceptibility loci from overall and
- 498 subtype-specific analyses. Nature Genetics. Nat Genet; 2020;52:572–81.
- 3. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis
  identifies 65 new breast cancer risk loci. Nature. Europe PMC Funders; 2017;551:92–4.
- 4. Mancuso N, Gayther S, Gusev A, Zheng W, Penney KL, Kote-Jarai Z, et al. Large-scale
- 502 transcriptome-wide association study identifies new prostate cancer risk regions. Nature
- 503 Communications [Internet]. Nature Publishing Group; 2018;9. Available from:
- 504 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172280/
- 505 5. Li Q, Seo JH, Stranger B, McKenna A, Pe'Er I, Laframboise T, et al. A novel eQTL-based 506 analysis reveals the biology of breast cancer risk loci. Cell. NIH Public Access;
- 507 2013;152:633-633.
- Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding
   RNAs. Cell. NIH Public Access; 2018;172:393–393.
- 510 7. Abascal F, Acosta R, Addleman NJ, Adrian J, Afzal V, Aken B, et al. Expanded
- 511 encyclopaedias of DNA elements in the human and mouse genomes. Nature. Nature
- 512 Research; 2020;583:699–710.

- 8. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its
- 514 biological functions. Nature Reviews Molecular Cell Biology 2020 22:2. Nature Publishing

515 Group; 2020;22:96–118.

- 516 9. Vance KW, Ponting CP. Transcriptional regulatory functions of nuclear long noncoding
- 517 RNAs. Trends in Genetics. Elsevier; 2014;30:348–348.
- 518 10. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nature Reviews

519 Cancer 2017 18:1. Nature Publishing Group; 2017;18:5–18.

- 520 11. Chen DL, Chen LZ, Lu YX, Zhang DS, Zeng ZL, Pan ZZ, et al. Long noncoding RNA XIST
- 521 expedites metastasis and modulates epithelial–mesenchymal transition in colorectal

522 cancer. Cell Death & Disease 2017 8:8. Nature Publishing Group; 2017;8:e3011–e3011.

523 12. Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. Cell. Cell;

524 2019;179:1033–55.

525 13. Arun G, Diermeier SD, Spector DL. Therapeutic Targeting of Long Non-Coding RNAs in

526 Cancer. Trends in molecular medicine. NIH Public Access; 2018;24:257–257.

527 14. Kamada S, Takeiwa T, Ikeda K, Horie-Inoue K, Inoue S. Long Non-coding RNAs Involved

in Metabolic Alterations in Breast and Prostate Cancers. Frontiers in Oncology. Frontiers
 Madia S. A.: 2020;10:2110, 2110.

- 529 Media S.A.; 2020;10:2119–2119.
- 530 15. Peterson SM, Thompson JA, Ufkin ML, Sathyanarayana P, Liaw L, Congdon CB. Common

531 features of microRNA target prediction tools. Frontiers in Genetics. Frontiers Research

532 Foundation; 2014;5:23–23.

533 16. Porcu E, Sadler MC, Lepik K, Auwerx C, Wood AR, Weihs A, et al. Differentially expressed

- genes reflect disease-induced rather than disease-causing changes in the transcriptome.
- 535 Nature Communications 2021 12:1. Nature Publishing Group; 2021;12:1–9.

536 17. Pierce BL, Tong L, Chen LS, Rahaman R, Argos M, Jasmine F, et al. Mediation Analysis

537 Demonstrates That Trans-eQTLs Are Often Explained by Cis-Mediation: A Genome-Wide

538 Analysis among 1,800 South Asians. PLoS Genetics. Public Library of Science; 2014;10.

- 539 18. Pierce BL, Tong L, Argos M, Demanelis K, Jasmine F, Rakibuz-Zaman M, et al. Co-
- 540 occurring expression and methylation QTLs allow detection of common causal variants and
- shared biological mechanisms. Nature Communications. Nature Publishing Group;
- 542 2018;9:1–12.
- 543 19. Yang F, Gleason KJ, Wang J, Duan J, He X, Pierce BL, et al. CCmed: cross-condition
- 544 mediation analysis for identifying replicable trans-associations mediated by cis-gene
- 545 expression. Bioinformatics. Oxford Academic; 2021;37:2513–20.
- 546 20. Yang F, Wang J, Pierce BL, Chen LS. Identifying cis-mediators for trans-eQTLs across
- 547 many human tissues using genomic mediation analysis. Genome Research. Cold Spring
  548 Harbor Laboratory Press; 2017;27:1859–71.
- 549 21. Bhattacharya A, Li Y, Love MI. MOSTWAS: Multi-Omic Strategies for Transcriptome-Wide
  550 Association Studies. Zhu X, editor. PLoS Genetics. 2021;17:e1009398–e1009398.
- 551 22. Bhattacharya A, Freedman AN, Avula V, Harris R, Liu W, Pan C, et al. Placental genomics
- 552 mediates genetic associations with complex health traits and disease. Nat Commun.
- 553 Nature Publishing Group; 2022;13:706.
- Shan N, Wang Z, Hou L. Identification of trans-eQTLs using mediation analysis with
   multiple mediators. BMC Bioinformatics. BioMed Central Ltd.; 2019;20.
- Liu X, Mefford JA, Dahl A, He Y, Subramaniam M, Battle A, et al. GBAT: a gene-based
  association test for robust detection of trans-gene regulation. Genome Biology. Genome
  Biology; 2020;21:211–211.
- 559 25. Aguet F, Barbeira AN, Bonazzola R, Brown A, Castel SE, Jo B, et al. The GTEx
- 560 Consortium atlas of genetic regulatory effects across human tissues. Science. American
  561 Association for the Advancement of Science; 2020;369:1318–30.
- 562 26. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The
- 563 cancer genome atlas pan-cancer analysis project. Nature Genetics. Nature Publishing
- 564 Group; 2013;45:1113–20.

- 565 27. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.
- 566 Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using
- 567 Summary Statistics. Williams SM, editor. PLoS Genetics. Public Library of Science;
- 568 2014;10:e1004383-e1004383.
- 569 28. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BWJH, et al. Integrative approaches
- 570 for large-scale transcriptome-wide association studies. Nature Genetics. 2016;48:245–52.
- 571 29. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of
- 572 genomic datasets with the R/Bioconductor package biomaRt. Nature Protocols 2009 4:8.
- 573 Nature Publishing Group; 2009;4:1184–91.
- 30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A
- Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am J
  Hum Genet. 2007;81:559–75.
- 577 31. Mostafavi S, Battle A, Zhu X, Urban AE, Levinson D, Montgomery SB, et al. Normalizing
- 578 RNA-Sequencing Data by Modeling Hidden Covariates with Prior Knowledge. PLoS ONE.
- 579 Public Library of Science; 2013;8:e68141–e68141.
- 580 32. van Iterson M. mvaniterson/Rhcpp: A fast R implementation using Rcpp based on the
- 581 original matlab HCP method for Normalizing RNA-Sequencing Data by Modeling Hidden
- 582 Covariates with Prior Knowledge [Internet]. 2020. Available from:
- 583 https://github.com/mvaniterson/Rhcpp
- 584 33. Shabalin AA. Gene expression Matrix eQTL: ultra fast eQTL analysis via large matrix
- 585 operations. Bioinformatics (Oxford, England). Oxford University Press; 2012;28:1353–8.
- 586 34. Saha A, Battle A. False positives in trans-eQTL and co-expression analyses arising from
- 587 RNA-sequencing alignment errors [version 2; peer review: 3 approved]. F1000Research.
- 588 F1000 Research Ltd; 2019;7:1860–1860.
- 589 35. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait
- analysis. American journal of human genetics. Elsevier; 2011;88:76–82.

- 591 36. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via
   592 Coordinate Descent. Journal of Statistical Software. 2010;33:1–22.
- 593 37. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable
- selection in regression, with application to genetic fine mapping. Journal of the Royal
- 595 Statistical Society: Series B. Blackwell Publishing Ltd; 2020;82:1273–300.
- 596 38. Endelman JB. Ridge Regression and Other Kernels for Genomic Selection with R Package
- 597 rrBLUP. The Plant Genome. 2011;4:250–5.
- 598 39. Carrasco AM, Acosta O, Ponce J, Cotrina J, Aguilar A, Araujo J, et al. PUM1 and RNase P
- 599 genes as potential cell-free DNA markers in breast cancer. Journal of Clinical Laboratory

600 Analysis. John Wiley & Sons, Ltd; 2021;35:e23720–e23720.

- 40. Shi P, Zhang J, Li X, Li W, Li H, Fu P. Long non-coding RNA NORAD inhibition upregulates
- microRNA-323a-3p to suppress tumorigenesis and development of breast cancer through
- 603 the PUM1/eIF2 axis. https://doi.org/101080/1538410120211934627. Taylor & Francis;
- 604 2021;20:1295–307.
- 41. Shi H, Li H, Yuan R, Guan W, Zhang X, Zhang S, et al. PCBP1 depletion promotes
- 606 tumorigenesis through attenuation of p27Kip1 mRNA stability and translation. Journal of
- 607 Experimental & Clinical Cancer Research 2018 37:1. BioMed Central; 2018;37:1–18.
- Goulding H, Jasani B, Pereira H, Reid A, Galea M, Bell J, et al. Metallothionein expression
  in human breast cancer. British Journal of Cancer 1995 72:4. Nature Publishing Group;
- 610 1995;72:968–72.
- 611 43. Si M, Lang J. The roles of metallothioneins in carcinogenesis. Journal of Hematology &
  612 Oncology 2018 11:1. BioMed Central; 2018;11:1–20.
- 613 44. Michmerhuizen AR, Spratt DE, Pierce LJ, Speers CW. ARe we there yet? Understanding
- androgen receptor signaling in breast cancer. npj Breast Cancer 2020 6:1. Nature

615 Publishing Group; 2020;6:1–19.

- 45. Masi M, Garattini E, Bolis M, Di Marino D, Maraccani L, Morelli E, et al. OXER1 and
- 617 RACK1-associated pathway: a promising drug target for breast cancer progression.
- 618 Oncogenesis 2020 9:12. Nature Publishing Group; 2020;9:1–15.
- 46. Zhang L, Pattanayak A, Li W, Ko H-K, Fowler G, Gordon R, et al. A Multifunctional Therapy
- 620 Approach for Cancer: Targeting Raf1 Mediated Inhibition of Cell Motility, Growth, and
- 621 Interaction with the Microenvironment. Molecular Cancer Therapeutics. American
- Association for Cancer Research; 2020;19:39–51.
- 47. Wang B, Wang X, Long JE, Eastham-Anderson J, Firestein R, Junttila MR. Castration-
- Resistant Lgr5+ Cells Are Long-Lived Stem Cells Required for Prostatic Regeneration.
- 625 Stem Cell Reports. Elsevier; 2015;4:768–768.
- 48. Abaffy T, Bain JR, Muehlbauer MJ, Spasojevic I, Lodha S, Bruguera E, et al. A
- 627 Testosterone Metabolite 19-Hydroxyandrostenedione Induces Neuroendocrine Trans-
- 628Differentiation of Prostate Cancer Cells via an Ectopic Olfactory Receptor. Frontiers in
- 629 Oncology. Frontiers; 2018;0:162–162.
- 49. Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H. Activation of an Olfactory
- 631 Receptor Inhibits Proliferation of Prostate Cancer Cells. The Journal of Biological
- 632 Chemistry. American Society for Biochemistry and Molecular Biology; 2009;284:16218–
- 633 16218.
- 50. Maine EA, Westcott JM, Prechtl AM, Dang TT, Whitehurst AW, Pearson GW. The cancer-
- 635 testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget.
- 636 Impact Journals, LLC; 2016;7:14708–14708.
- 637 51. Quiroz-Zárate A, Harshfield BJ, Hu R, Knoblauch N, Beck AH, Hankinson SE, et al.
- 638 Expression Quantitative Trait loci (QTL) in tumor adjacent normal breast tissue and breast
- tumor tissue. Wong K-K, editor. PLOS ONE. Public Library of Science; 2017;12:e0170181–
- e0170181.

- 641 52. Sun C-C, Zhu W, Li S-J, Hu W, Zhang J, Zhuo Y, et al. FOXC1-mediated LINC00301
- 642 facilitates tumor progression and triggers an immune-suppressing microenvironment in
- 123 non-small cell lung cancer by regulating the HIF1 $\alpha$  pathway. Genome Medicine 2020 12:1.
- 644 BioMed Central; 2020;12:1–27.
- 53. Tuna M, Machado AS, Calin GA. Genetic and epigenetic alterations of microRNAs and
- 646 implications for human cancers and other diseases. Genes Chromosomes and Cancer.
- 647 Blackwell Publishing Inc.; 2016;55:193–214.
- 54. Xiao L, Zhou J, Liu H, Zhou Y, Chen W, Cui W, et al. RNA Sequence Profiling Reveals
- 649 Unique Immune and Metabolic Features of Breast Cancer Brain Metastases. Frontiers in
   650 Oncology. Frontiers; 2021;0:3213–3213.
- 651 55. MC B, U Y, MO B, O S, A B. Tamoxifen inhibits cytochrome P450 2C9 activity in breast
- cancer patients. Journal of chemotherapy (Florence, Italy). J Chemother; 2006;18:421–4.
- 653 56. Cai P, Lu Z, Wu J, Qin X, Wang Z, Zhang Z, et al. BTN3A2 serves as a prognostic marker
- and favors immune infiltration in triple-negative breast cancer. Journal of Cellular
- 655 Biochemistry. John Wiley & Sons, Ltd; 2020;121:2643–54.
- 656 57. MS AF, X G, SS F, W A-J, Z B, PR R, et al. The increased expression of fatty acid-binding
- 657 protein 9 in prostate cancer and its prognostic significance. Oncotarget. Oncotarget;
- 658 2016;7:82783–97.
- 659 58. MJ M, S L, NE A, CA H, D A, A B, et al. Association of type 2 diabetes susceptibility
- 660 variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort
- 661 Consortium. American journal of epidemiology. Am J Epidemiol; 2012;176:1121–9.
- 662 59. Marín-Aguilera M, Reig Ò, Lozano JJ, Jiménez N, García-Recio S, Erill N, et al. Molecular
- 663 profiling of peripheral blood is associated with circulating tumor cells content and poor
- 664 survival in metastatic castration-resistant prostate cancer. Oncotarget. Impact Journals,

665 LLC; 2015;6:10604–10604.

- 666 60. Saigo C, Kito Y, Takeuchi T. Cancerous Protein Network That Inhibits the Tumor
- 667 Suppressor Function of WW Domain-Containing Oxidoreductase (WWOX) by Aberrantly
- 668 Expressed Molecules. Frontiers in Oncology. Frontiers; 2018;0:350–350.
- 669 61. S F, J W, Y Z, CJ C, M I. FGF23 promotes prostate cancer progression. Oncotarget.
- 670 Oncotarget; 2015;6:17291–301.
- 671 62. Li Y-L, Tian H, Jiang J, Zhang Y, Qi X-W. Multifaceted regulation and functions of fatty acid
- desaturase 2 in human cancers. American Journal of Cancer Research. e-Century
- 673 Publishing Corporation; 2020;10:4098–4098.
- 674 63. Chi J-R, Yu Z-H, Liu B-W, Zhang D, Ge J, Yu Y, et al. SNHG5 Promotes Breast Cancer
- 675 Proliferation by Sponging the miR-154-5p/PCNA Axis. Molecular Therapy Nucleic Acids.
- 676 Elsevier; 2019;17:138–49.
- 677 64. Damas ND, Marcatti M, Côme C, Christensen LL, Nielsen MM, Baumgartner R, et al.
- 678 SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA
- destabilization. Nature Communications 2016 7:1. Nature Publishing Group; 2016;7:1–14.
- 680 65. Wang M, Takahashi A, Liu F, Ye D, Ding Q, Qin C, et al. Large-scale association analysis
- 681 in Asians identifies new susceptibility loci for prostate cancer. Nature Communications
- 682 2015 6:1. Nature Publishing Group; 2015;6:1–7.
- 683 66. Sinnott-Armstrong N, Seoane JA, Sallari R, Pritchard JK, Curtis C, Snyder MP. Convergent
- 684 mutations in tissue-specific regulatory regions reveal novel cancer drivers. bioRxiv. Cold

685 Spring Harbor Laboratory; 2020;2020.08.21.239954-2020.08.21.239954.

- 686 67. Kang D, Lee Y, Lee J-S. RNA-Binding Proteins in Cancer: Functional and Therapeutic
- 687 Perspectives. Cancers. Multidisciplinary Digital Publishing Institute (MDPI); 2020;12:1–33.
- 688 68. Hu C, Yang K, Li M, Huang W, Zhang F, Wang H. Lipocalin 2: a potential therapeutic target
- for breast cancer metastasis. OncoTargets and therapy. Dove Press; 2018;11:8099–8099.

- 690 69. Sack LM, Davoli T, Li MZ, Li Y, Xu Q, Naxerova K, et al. Profound Tissue Specificity in
- Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. Cell. NIH Public
   Access; 2018;173:499–499.
- 693 70. Zhang J, Xu T, Liu L, Zhang W, Zhao C, Li S, et al. LMSM: A modular approach for
- 694 identifying IncRNA related miRNA sponge modules in breast cancer. PLOS Computational
- Biology. Public Library of Science; 2020;16:e1007851.
- 696 71. Smith JC, Sheltzer JM. Genome-wide identification and analysis of prognostic features in
- 697 human cancers. bioRxiv. Cold Spring Harbor Laboratory; 2021;2021.06.01.446243-
- 698 2021.06.01.446243.
- Sun L, Zhang Y, Zhang C. Distinct Expression and Prognostic Value of MS4A in Gastric
  Cancer. Open Medicine. De Gruyter; 2018;13:178–178.
- 701 73. Hou R, Jiang L. LINC00115 promotes stemness and inhibits apoptosis of ovarian cancer
- stem cells by upregulating SOX9 and inhibiting the Wnt/ $\beta$ -catenin pathway through
- competitively binding to microRNA-30a. Cancer Cell International 2021 21:1. BioMed
- 704 Central; 2021;21:1–15.
- 705 74. Li Q, Wang X, Zhou L, Jiang M, Zhong G, Xu S, et al. A Positive Feedback Loop of Long
  706 Noncoding RNA LINC00152 and KLF5 Facilitates Breast Cancer Growth. Frontiers in
  707 Oncology. Frontiers; 2021;0:899–899.
- 708 75. Yuan C, Luo X, Duan S, Guo L. Long noncoding RNA LINC00115 promotes breast cancer
   709 metastasis by inhibiting miR-7. FEBS Open Bio. John Wiley & Sons, Ltd; 2020;10:1230–7.
- 710 76. Ma Y, Xu XL, Huang HG, Li YF, Li ZG. LncRNA TDRG1 promotes the aggressiveness of
- 711 gastric carcinoma through regulating miR-873-5p/HDGF axis. Biomedicine &
- 712 Pharmacotherapy. Elsevier Masson; 2020;121:109425–109425.
- 713 77. Hu X, Mu Y, Wang J, Zhao Y. LncRNA TDRG1 promotes the metastasis of NSCLC cell
- through regulating miR-873-5p/ZEB1 axis. Journal of Cellular Biochemistry. John Wiley &
- 715 Sons, Ltd; 2021;122:969–82.

- 716 78. Tracey LJ, Justice MJ. Off to a bad start: Cancer initiation by pluripotency regulator
- 717 PRDM14. Trends in genetics : TIG. NIH Public Access; 2019;35:489–489.
- 718 79. Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in
- 719 mammalian mRNAs. Izaurralde E, editor. eLife. eLife Sciences Publications, Ltd;
- 720 2015;4:e05005.
- McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, et al. The biochemical basis
  of microRNA targeting efficacy. Science. 2019;366:eaav1741.
- 723 81. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit
- with revamped UIs and APIs. Nucleic Acids Research. 2019;47:199–205.
- 725 82. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the
- pathogenesis, prognosis and treatment of solid tumours. British Journal of Cancer 2015
- 113:3. Nature Publishing Group; 2015;113:365–71.
- 728 83. Hoxhaj G, Manning BD. The PI3K–AKT network at the interface of oncogenic signalling and
- cancer metabolism. Nature Reviews Cancer 2019 20:2. Nature Publishing Group;
- 730 2019;20:74–88.
- Masjedi S, Zwiebel LJ, Giorgio TD. Olfactory receptor gene abundance in invasive breast
  carcinoma. Scientific Reports 2019 9:1. Nature Publishing Group; 2019;9:1–12.
- 733 85. Kalra S, Mittal A, Gupta K, Singhal V, Gupta A, Mishra T, et al. Analysis of single-cell
- transcriptomes links enrichment of olfactory receptors with cancer cell differentiation status
- and prognosis. Communications Biology 2020 3:1. Nature Publishing Group; 2020;3:1–10.
- 736 86. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development
- and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and
- molecular pathogenesis. Genes & Diseases. Chongqing Medical University; 2018;5:77–77.
- 739 87. Holle AW, Kalafat M, Ramos AS, Seufferlein T, Kemkemer R, Spatz JP. Intermediate
- filament reorganization dynamically influences cancer cell alignment and migration.
- Scientific Reports 2017 7:1. Nature Publishing Group; 2017;7:1–14.

742	88.	Ong MS, Den	g S. Halim CE.	, Cai W, Tan T	Z, Huang RYJ	, et al. C	ytoskeletal Proteins ir

- 743 Cancer and Intracellular Stress: A Therapeutic Perspective. Cancers [Internet].
- 744 Multidisciplinary Digital Publishing Institute (MDPI); 2020;12. Available from:
- 745 /pmc/articles/PMC7017214/
- 746 89. Tang Y, He Y, Zhang P, Wang J, Fan C, Yang L, et al. LncRNAs regulate the cytoskeleton
- and related Rho/ROCK signaling in cancer metastasis. Molecular Cancer 2018 17:1.
- 748 BioMed Central; 2018;17:1–10.
- 749 90. Strous GJ, Almeida ADS, Putters J, Schantl J, Sedek M, Slotman JA, et al. Growth
- 750 Hormone Receptor Regulation in Cancer and Chronic Diseases. Frontiers in
- 751 Endocrinology. Frontiers Media S.A.; 2020;11:867–867.
- 752 91. Hu CC, Liang YW, Hu JL, Liu LF, Liang JW, Wang R. LncRNA RUSC1-AS1 promotes the
- proliferation of breast cancer cells by epigenetic silence of KLF2 and CDKN1A. European
- review for medical and pharmacological sciences. Eur Rev Med Pharmacol Sci;
- 755 2019;23:6602–11.
- 756 92. Zhu L, Cui K, Weng L, Yu P, Du Y, Zhang T, et al. A panel of 8-IncRNA predicts prognosis
- of breast cancer patients and migration of breast cancer cells. PLOS ONE. Public Library of
   Science; 2021;16:e0249174–e0249174.
- 759 93. Yousaf N, Deng Y, Kang Y, Riedel H. Four PSM/SH2-B Alternative Splice Variants and

760 Their Differential Roles in Mitogenesis \*. Journal of Biological Chemistry. Elsevier;

- 761 2001;276:40940–8.
- 762 94. Cheng X, Wang J, Liu C, Jiang T, Yang N, Liu D, et al. Zinc transporter SLC39A13/ZIP13
- facilitates the metastasis of human ovarian cancer cells via activating Src/FAK signaling
- pathway. Journal of Experimental and Clinical Cancer Research. BioMed Central Ltd;
- 765 2021;40:1–15.

766 95. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, et al. Identification

and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.

768 Nature communications. NIH Public Access; 2013;4:1627–1627.

- 769 96. Ruiz-Arenas C, Cáceres A, Moreno V, González JR. Common polymorphic inversions at
- 17q21.31 and 8p23.1 associate with cancer prognosis. Human Genomics. BioMed Central
  Ltd.; 2019;13:1–9.
- 772 97. Orsetti B, Courjal F, Cuny M, Rodriguez C, Theillet C. 17q21-q25 aberrations in breast

cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance

among which two correspond to DNA amplification. Oncogene 1999 18:46. Nature

775 Publishing Group; 1999;18:6262–70.

776 98. O'Brien HE, Hannon E, Hill MJ, Toste CC, Robertson MJ, Morgan JE, et al. Expression

quantitative trait loci in the developing human brain and their enrichment in

neuropsychiatric disorders. Genome Biology [Internet]. BioMed Central; 2018;19. Available
 from: /pmc/articles/PMC6231252/

780 99. Trampush JW, Yang MLZ, Yu J, Knowles E, Davies G, Liewald DC, et al. GWAS meta-

analysis reveals novel loci and genetic correlates for general cognitive function: a report

from the COGENT consortium. Molecular Psychiatry 2017 22:3. Nature Publishing Group;

783 2017;22:336–45.

100. Wei XT, Feng GJ, Zhang H, Xu Q, Ni JJ, Zhao M, et al. Pleiotropic genomic variants at
17q21.31 associated with bone mineral density and body fat mass: a bivariate genomewide association analysis. European Journal of Human Genetics 2020 29:4. Nature

787 Publishing Group; 2020;29:553–63.

101. Bowles KR, Pugh DA, Farrell K, Han N, Tcw J, Liu Y, et al. 17q21.31 sub-haplotypes
 underlying H1-associated risk for Parkinson's disease are associated with LRRC37A/2

expression in astrocytes. bioRxiv. Cold Spring Harbor Laboratory; 2021;860668–860668.

791	102.	Boettger LM, Handsaker RE, Zody MC, Mccarroll SA. Structural haplotypes and recent
792		evolution of the human 17q21.31 region. Nature genetics. NIH Public Access;
793		2012;44:881–881.
794	103.	Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, et al. Modulation of long noncoding
795		RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet.
796		2016;48:1142–50.
797	104.	Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-
798		scale genotyping identifies 41 new loci associated with breast cancer risk. Nature
799		Genetics. 2013;45:353–61.
800	105.	Sirey TM, Roberts K, Haerty W, Bedoya-Reina O, Granados SR, Tan JY, et al. The long
801		non-coding rna cerox1 is a post transcriptional regulator of mitochondrial complex i
802		catalytic activity. eLife. eLife Sciences Publications Ltd; 2019;8.
803	106.	Deng X, Zhao Y, Wang B. miR-519d-mediated downregulation of STAT3 suppresses
804		breast cancer progression. Oncology reports. Oncol Rep; 2015;34:2188–94.
805	107.	Li D, Song H, Wu T, Xie D, Hu J, Zhao J, et al. MiR-519d-3p suppresses breast cancer
806		cell growth and motility via targeting LIM domain kinase 1. Molecular and cellular
807		biochemistry. Mol Cell Biochem; 2018;444:169–78.
808	108.	Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-full Z, et al. Transcriptome-wide
809		association study of breast cancer risk by estrogen-receptor status. Genetic
810		Epidemiology. John Wiley & Sons, Ltd; 2020;44:442–68.
811	109.	Gusev A, Lawrenson K, Lin X, Lyra PC, Kar S, Vavra KC, et al. A transcriptome-wide
812		association study of high-grade serous epithelial ovarian cancer identifies new
813		susceptibility genes and splice variants. Nature Genetics. Nature Publishing Group;
814		2019;51:815–23.

- 110. Pashirzad M, Fiuji H, Khazei M, Moradi-Binabaj M, Ryzhikov M, Shabani M, et al. Role of
- 816 Wnt3a in the pathogenesis of cancer, current status and prospective. Molecular Biology
- 817 Reports. Springer Netherlands; 2019;46:5609–16.
- 111. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, et al. Expression of Wnt3
- 819 activates Wnt/ $\beta$ -catenin pathway and promotes EMT-like phenotype in trastuzumab-
- resistant HER2-overexpressing breast cancer cells. Molecular cancer research : MCR.
- 821 Mol Cancer Res; 2012;10:1597–606.
- 112. Zhou JX, Yang X, Ning S, Wang L, Wang K, Zhang Y, et al. Identification of KANSARL as
- the first cancer predisposition fusion gene specific to the population of European ancestry

origin. Oncotarget. Impact Journals, LLC; 2017;8:50594–50594.

- 113. Wu W, Li D, Feng X, Zhao F, Li C, Zheng S, et al. A pan-cancer study of selenoprotein
- genes as promising targets for cancer therapy. BMC Medical Genomics. BioMed Central
  Ltd; 2021;14:1–14.
- 114. Yu Y, Hu H, Doust AN, Kellogg EA. Divergent gene expression networks underlie

829 morphological diversity of abscission zones in grasses. New Phytologist.

830 2019;nph.16087-nph.16087.

115. de Jong S, Chepelev I, Janson E, Strengman E, van den Berg LH, Veldink JH, et al.

Common inversion polymorphism at 17q21.31 affects expression of multiple genes in
 tissue-specific manner. BMC Genomics. BioMed Central; 2012;13:1–6.

Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, et al. A transcriptome-wide
association study among 97,898 women to identify candidate susceptibility genes for
epithelial ovarian cancer risk. Cancer Research. Cancer Res; 2018;78:5419–30.

117. Su X, Li W, Lv L, Li X, Yang J, Luo XJ, et al. Transcriptome-Wide Association Study

838 Provides Insights Into the Genetic Component of Gene Expression in Anxiety. Frontiers in

839 Genetics. Frontiers Media S.A.; 2021;12:1901–1901.

- 118. Lee CT, Bendriem RM, Kindberg AA, Worden LT, Williams MP, Drgon T, et al. Functional
- 841 Consequences of 17q21.31/WNT3-WNT9B Amplification in hPSCs with Respect to
- Neural Differentiation. Cell Reports. Cell Press; 2015;10:616–32.
- 119. Zhang D, Guelfi S, Garcia-Ruiz S, Costa B, Reynolds RH, D'Sa K, et al. Incomplete
- 844 annotation has a disproportionate impact on our understanding of Mendelian and
- 845 complex neurogenetic disorders. Science Advances. American Association for the
- 846 Advancement of Science; 2020;6:8299–8299.
- 120. Giambartolomei C, Liu JZ, Zhang W, Hauberg M, Shi H, Boocock J, et al. A Bayesian
- 848 framework for multiple trait colocalization from summary association statistics.
- Bioinformatics. Oxford University Press; 2018;34:2538–45.
- 121. Gleason KJ, Yang F, Pierce BL, He X, Chen LS. Primo: Integration of multiple GWAS and
- 851 omics QTL summary statistics for elucidation of molecular mechanisms of trait-associated
- SNPs and detection of pleiotropy in complex traits. Genome Biology. BioMed Central Ltd;
  2020;21:236–236.
- 122. Bhattacharya A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI. A
- framework for transcriptome-wide association studies in breast cancer in diverse study
  populations. Genome Biology. BioMed Central; 2020;21:42–42.
- 123. Geeleher P, Nath A, Wang F, Zhang Z, Barbeira AN, Fessler J, et al. Cancer expression
- quantitative trait loci (eQTLs) can be determined from heterogeneous tumor gene
- expression data by modeling variation in tumor purity. Genome Biology. BioMed Central;
  2018;19:130–130.
- 124. Patel A, Garcia-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, et al. Gene level
- germline contributions to clinical risk of recurrence scores in Black and White breast
- 863 cancer patients. Cancer Research. American Association for Cancer Research;
- 864 2021;canres.1207.2021-canres.1207.2021.
- 865

## 866 **ACKNOWLEDGEMENTS**

- 867 We thank Nicholas Mancuso, Harold Pimentel, Mike Love, Achal Patel, and Kangcheng Hou for
- 868 engaging conversation during the research process. We also thank the UCLA Bruins-in-
- 869 Genomics Summer Program for the research opportunities.
- 870
- The Prostate cancer genome-wide association analyses are supported by the Canadian
- 872 Institutes of Health Research, European Commission's Seventh Framework Programme grant
- agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357,

874 C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The

875 National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA

- 148537-01 (the GAME-ON initiative).
- 877

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA
148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and
X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number
HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic
support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

883

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now PCUK), The Orchid Cancer Appeal, Rosetrees Trust, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

890

The breast cancer genome-wide association analyses for BCAC and CIMBA were supported by 891 892 Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710, C12292/A20861, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, 893 C8197/A16565), The National Institutes of Health (CA128978, X01HG007492- the DRIVE 894 895 consortium), the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and the 896 Ministère de l'Économie, Science et Innovation du Québec through Genome Québec and the 897 PSRSIIRI-701 grant, the Quebec Breast Cancer Foundation, the European Community's 898 899 Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), the European Union's Horizon 2020 Research and Innovation Programme (634935 900 and 633784), the Post-Cancer GWAS initiative (U19 CA148537, CA148065 and CA148112 -901 the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian 902 903 Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer (CRN-87521), the Komen Foundation for the Cure, the Breast Cancer Research Foundation 904 and the Ovarian Cancer Research Fund. All studies and funders are listed in Zhang H et al (Nat 905 906 Genet, 2020).

907

#### 908 FUNDING

TS was supported by the National Institute of Neurological Disorders and Stroke of the National 909 910 Institutes of Health under Award Number T32NS048004. This research was supported by the 911 National Institute of Mental Health of the National Institutes of Health under Award number 912 5R01MH115676-04. AG was partially supported by R01 CA227237. SL was partially supported by NIH award R01 CA194393. BP were partially supported by NIH awards R01 HG009120, R01 913 914 MH115676, R01 CA251555, R01 Al153827, R01 HG006399, R01 CA244670, U01 HG011715. 915 The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. 916


### 917

#### 918 AUTHOR INFORMATION


- 919 Contributions
- AB conceived the study. AB, TS, and PL developed the statistical approaches, performed the
- analysis, and drafted the paper. AB, TS, and BP provided insight in methodological approaches
- and analysis. BP provided data resources. AB and BP supervised the study. All authors
- 923 approved and edited the final manuscript.
- 924
- 925 Corresponding author
- 926 Correspondence to Arjun Bhattacharya (abtbhatt@ucla.edu)
- 927

## 928 ETHICS DECLARATION


- 929 Ethics approval and consent to participate
- 930 This study was approved by the Office of Human Research Ethics at the University of California,
- 1931 Los Angeles, and written informed consent was obtained from each participant. All experimental
- 932 methods abided by the Helsinki Declaration.
- 933
- 934 Consent for publication
- 935 Not applicable.
- 936
- 937 Competing interests
- 938 The authors declare that they have no competing interests.




**Figure 1**: Schematic of mediation analysis to identify ncRNA-mediated distal-eQTLs of proteincoding genes. A SNP s is distal to protein-coding gene G and local to ncRNA M, where M has some distal regulatory effect on G. We use expression quantitative trait locus mapping to identify the local-eQTL between s and M (green dotted line) and the distal-eQTL between s and G (grey dotted line). Using either mediation analysis or gene-level association testing, we estimate the indirect mediation effect of s on G through effects from M (red line). Lastly, we use colocalization and genetically-regulated expression analysis to find any intersecting genetic signal between distal-eQTLs of G and genetic associations with breast and prostate cancer risk.




**Figure 2**: Location plot of distal-eQTL or gene-gene associations across healthy and tumor samples of breast and prostate tissue. (a) eSNP (X-axis) position vs. transcription start site (TSS) of pcGene (Y-axis) at FDR-adjusted P < 0.01, sized by absolute scaled TME and colored by direction of effect. (b) ncRNA TSS (X-axis) vs. pcGene TSS (Y-axis) at FDR-adjusted P < 0.01, sized by absolute scaled gene-gene effect and colored by direction of effect. Top cross-chromosomal distal-eGenes with largest effects are labeled.




**Figure 3**: Over-represented ontologies for tissue-specific eGenes. -log<sub>10</sub> P-value of enrichment (X-axis) of over-represented gene sets (Y-axis), with point sized by enrichment ratio and colored by ontology category. Here, for a tissue, we compare the set of pcGenes from healthy or tumor state to the universe of all pcGenes for tissue across both healthy and tumor states.



**Figure 4**: Colocalization of local-eQTLs of ncRNA and distal-eQTLs of pcGene with GWAS. (a) Barplot of numbers of mediating ncRNAs within 1 Megabase of a GWAS SNP (X-axis) from cancers (Y-axis). (b-d) Colocalization results for example ncRNAs and pcGenes, with phenotype in the GWAS, ncRNA, and pcGene provided. Left panel shows scatterplot of absolute Z-scores of GWAS (X-axis) and eQTL associations (Y-axis) with points colored by posterior probability of colocalization (PP.H4). Right panel shows a Manhattan plot of GWAS (top), ncRNA local-eQTL (middle), and pcGene distal-eQTL (bottom) signal, colored by PP.H4.



**Figure 5**: *Impact of H2 inversion on eQTLs in the 17q21.31 locus.* (a) Causal diagram of genetic effects in 17q21.31, where strong effects of genetically-determined H2 inversion on ncRNA and pcGene (in black) induces the observed SNP-ncRNA and -pcGene associations (in grey). (b) Forest plot of effect sizes and 95% confidence interval (Y-axis) on H2 inversion on pcGenes or ncRNAs (X-axis). (c) Difference in -log10 permutation P-value (Y-axis) of total mediation effect of ncRNA on pcGene, with or without adjustment for H2 inversion (X-axis). (d) Manhattan plots of GWAS, local-eQTLs of KANSL-AS1, and distal-eQTLs of CRHR1, unadjusted (left) and adjusted (right) for H2 inversion, colored by per-SNP PP.H4. (e) Scatterplot of Z-score of local-eQTLs on KANSL1-AS1 (X-axis) against Z-score of local-QTLs of H2 inversion, colored by per-SNP PP.H4.



**Figure 6**: *GReX* associations with cancer risk for ncRNAs mediating multiple distal-eQTLs of pcGenes. Forest plot of effect size and confidence intervals at significance level of  $P = 2.5 \times 10^{-6}$  (Y-axis) of GReX-associations with overall and subtype-specific cancer risk across ncRNAs that showed significant mediation of multiple distal-eQTLs of distinct pcGenes (X-axis) in non-cancerous (a) and tumor (b) tissue states.

# TABLES

-


	Breast		Prostate	
	Non- cancerous	Tumor	Non- cancerous	Tumor
Total eQTLs				
Local	22,832	1,298	12,511	6,368
Distal	29,512	316,097	31,782	363,587
Total eGenes				
local-ncRNAs	1,113	87	773	60
distal-pcGenes	8,849	19,376	8,711	15,560
SNPs associated in both local and distal eQTLs				
Local	1,569	601	281	6,368
Distal	1,580	5,089	264	9,259
Mediated distal-eQTLs				
eSNPs	703	3,017	103	425
e-ncRNAs	157	45	22	18
e-pcGenes	173	562	24	107

**Table 1**: Summary of local- and distal-eQTL mapping results across breast and prostate non-cancerous and tumor tissue through mediation analysis.


**Table 2**: Summary of distal-eQTL mapping results across breast and prostate normal and tumor tissue using GBAT.

	Breast		Prostate	
	Normal	Tumor	Normal	Tumor
Total gene-gene associations	13	1,375	7	297
Unique ncRNAs	9	209	4	84
Unique pcGenes	10	1,127	5	268


## SUPPLEMENTAL FIGURES




**Supplemental Figure S1**: *Analysis scheme*. We analyze genetic and transcriptomic data from non-cancerous breast and prostate tissue from GTEx and breast and prostate tumors from TCGA. We optimize eQTL mapping using ordinary least squares regression for numbers of genotype principal components and expression hidden covariates with prior to optimize eQTL discovery. We then conduct a genome-wide local and distal eQTL analysis using the optimized set of covariates. Next, we conduct mediation analysis or gene-based association testing to identify distal-eQTLs of pcGenes that are mediated by local-eQTLs of ncRNAs. Lastly, we integrate eQTLs results with GWAS using colocalization and analysis of genetically-regulated expression.




**Supplemental Figure S2:** Distribution of total mediation effects, mediation proportions, and gene-level distal effect sizes in healthy and tumor breast and prostate tissue.




**Supplemental Figure S3**: Over-represented ontologies for healthy- or tumor-specific eGenes, compared to all protein-coding genes in the transcriptome. -log<sub>10</sub> P-value of enrichment (X-axis) of over-represented gene sets (Y-axis), with point sized by enrichment ratio and colored by ontology category. Here, combining pcGenes with a distal genetic association across breast and prostate tissue, we compare the set of pcGenes from healthy or tumor state to the universe of all pcGenes in the transcriptome.



**Supplemental Figure S4**: Over-represented ontologies for healthy or tumor state-specific eGenes, compared to all protein-coding genes detected in distal-QTL mapping.  $-\log_{10}$  P-value of enrichment (X-axis) of over-represented gene sets (Y-axis), with point sized by enrichment ratio and colored by ontology category. Here, combining pcGenes with a distal genetic association across breast and prostate tissue, we compare the set of pcGenes detected for breast or prostate and compare to the universe of all pcGenes detected across breast and prostate. No enrichments at P < 0.05 were detected for breast-specific pcGenes.



**Supplemental Figure S5**: Over-represented ontologies for breast or prostate-specific eGenes, compared to all protein-coding genes detected in distal-QTL mapping.  $-\log_{10}$  P-value of enrichment (X-axis) of over-represented gene sets (Y-axis), with point sized by enrichment ratio and colored by ontology category. Here, combining pcGenes with a distal genetic association across healthy and tumor state, we compare the set of pcGenes detected for breast or prostate and compare to the universe of all pcGenes detected across breast and prostate. No enrichments at P < 0.05 were detected for breast-specific pcGenes.



**Supplemental Figure S6**: Scatterplot of posterior probability of colocalization for local- and distal-eQTLs with cancer risk GWAS. Red lines show PP.H4 = .75.

### SUPPLEMENTAL TABLE LEGENDS

**Table S1:** *Prioritized ncRNA-mediated distal-eQTLs of pcGenes in healthy and tumor prostate tissue.* We provide the tissue state (healthy or tumor), SNP, ncRNA, pcGene, effect size, P-value, method of detection (mediation analysis or GBAT), and closest GWAS risk SNP and P-value.

**Table S2:** *Prioritized ncRNA-mediated distal-eQTLs of pcGenes in healthy and tumor breast tissue.* We provide the tissue state (healthy or tumor), SNP, ncRNA, pcGene, effect size, P-value, method of detection (mediation analysis or GBAT), and closest GWAS risk SNP and P-value.

 Table S3: In-silico validation of miRNA-pcGene pairs using TargetScan. For miRNAs detected

 to mediated distal-eQTLs of pcGenes, we list miRNAs shown to target the pcGene using

 TargetScan.

**Table S4:** Colocalization results for ncRNA-mediated distal-eQTLs with GWAS signal of cancer risk. We provide the trait, tissue (breast or prostate), tissue state (healthy or tumor), ncRNA and its location, pcGene and its location, posterior probabilities of colocalization between the ncRNA and pcGene with the GWAS signal, and the colocalized SNP for each signal.

**Table S5:** *GReX analysis results for ncRNAs and cancer risk.* We provide the trait, tissue (breast or prostate), tissue state (healthy or tumor), ncRNA and its location, effect size, standard error, and Z-score of association.